Bluebird bio, inc. (BLUE)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Net loss

-827,773

-789,608

-715,284

-654,733

-604,945

-555,625

-523,830

-457,152

-382,057

-335,643

-289,779

-288,000

-275,945

-263,507

-239,418

-205,319

-198,270

-166,783

-139,052

-113,156

-62,887

-48,709

-37,246

-26,329

-29,386

-25,321

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of contingent consideration

-657

2,747

3,468

2,713

2,761

2,999

114

-1,856

-3,088

-2,189

-884

2,137

3,095

2,675

2,428

1,157

3,142

2,344

0

0

0

-

-

-

-

-

-

-

-

Depreciation and amortization

18,531

17,434

16,923

16,790

16,921

17,158

16,252

15,456

14,714

13,538

12,415

11,182

10,209

9,648

9,170

8,657

7,992

7,419

7,051

6,720

5,463

4,228

2,889

1,654

1,277

941

0

0

0

Stock-based compensation expense

164,581

160,629

155,985

147,237

120,182

110,836

95,178

79,362

64,796

53,282

47,878

43,801

41,094

39,756

40,940

40,564

45,831

41,120

34,017

27,402

13,702

10,763

9,415

9,016

8,323

6,491

0

0

0

Unrealized loss on equity securities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-cash items

8,931

11,000

18,348

15,778

11,739

5,880

-8,804

-8,321

-6,394

-3,153

-2,446

-2,054

-2,855

-2,825

3,151

2,807

2,251

1,513

0

0

0

-

-

-

-

-

-

-

-

Issuance of restricted common stock in exchange for consulting services to non-employees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Re-measurement of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

440

0

0

0

Loss on disposal of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other assets

12,104

13,913

15,946

41,703

23,595

24,288

26,241

13,777

30,473

20,092

23,326

22,190

15,152

14,318

7,987

7,510

9,116

6,847

2,576

1,606

1,759

-307

145

2,454

1,077

4,214

0

0

0

Operating lease right-of-use assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

3,491

23,600

27,387

6,169

14,941

3,614

480

2,620

3,046

526

5,001

11,793

5,596

6,658

3,128

-173

677

2,541

978

35

-192

-2,249

484

781

272

2,067

0

0

0

Accrued expenses and other liabilities

47,248

46,291

21,626

18,742

11,777

37,832

43,782

24,146

23,707

5,848

-8,516

11,045

8,522

22,051

28,202

10,822

9,546

9,423

9,676

3,393

8,319

9,969

5,126

7,818

2,984

761

0

0

0

Operating lease liabilities

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-10,120

-16,674

-24,447

-31,999

-36,578

-41,872

-34,041

-12,883

-8,973

1,024

1,532

-10,786

-8,626

4,565

4,645

5,124

26,737

11,171

6,777

1,515

-24,880

-24,871

-25,340

-25,341

-25,340

54,868

0

0

0

Collaboration research advancement

6,075

5,739

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

0

1,390

-

2,115

619

174

-330

-654

140

1,254

2,110

6,799

8,904

7,997

7,408

0

0

0

Net cash used in operating activities

-616,346

-564,400

-535,139

-496,231

-458,758

-413,426

-379,074

-360,938

-314,072

-280,553

-254,280

-237,384

-228,184

-189,647

-153,626

-143,252

-111,036

-98,429

-81,008

-72,712

-71,918

-59,693

-49,484

-37,573

-34,502

43,450

0

0

0

Cash flows from investing activities:
Purchase of property, plant and equipment, including assets under financing lease obligation

62,383

71,028

71,531

72,973

67,606

55,737

61,678

43,422

43,670

62,242

56,432

61,481

50,159

28,029

18,442

10,544

9,793

7,055

6,023

6,742

7,347

8,708

11,593

11,939

10,375

8,670

0

0

0

Purchases of marketable securities

476,256

756,570

1,337,756

1,300,184

1,497,304

1,517,982

0

0

0

-

-

384,120

402,990

348,225

429,811

574,580

560,330

755,175

0

0

0

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

1,313,161

1,340,629

1,296,957

1,181,447

1,113,287

894,284

743,306

638,646

472,446

431,816

406,870

427,349

451,359

443,364

423,624

363,324

264,494

199,179

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

769,298

507,807

-96,537

-191,710

-451,623

-679,435

-230,752

-663,403

-576,901

-316,630

-476,777

-18,461

-1,790

67,110

-21,508

-230,766

-314,445

-571,867

-323,099

-348,955

-347,652

-157,193

-190,078

-16,512

-11,528

-9,823

0

0

0

Reimbursement of assets under financing lease obligation

-

-

-

-

-

3,098

3,098

4,720

27,288

38,021

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on financing lease obligation

-

-

-

-

-

1,017

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock

-

-

-

-

-

649,368

1,641,531

1,046,633

1,052,231

1,006,570

245,582

242,248

237,363

234,962

4,986

5,941

8,284

10,109

11,760

8,851

7,019

5,226

0

0

0

-

-

-

-

Accumulated issuance costs of planned initial public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from exercise of stock options and ESPP contributions

11,927

21,187

21,391

21,139

21,998

31,759

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash provided by financing activities

11,927

21,187

21,103

675,718

676,238

737,692

1,324,102

671,429

1,130,980

1,076,174

727,616

723,929

257,766

241,534

2,778

3,348

484,895

486,720

732,014

839,256

360,245

358,452

112,374

948

106,693

105,641

0

0

0

Increase (decrease) in cash, cash equivalents and restricted cash

164,874

-35,390

-610,573

-12,223

-234,143

-355,169

714,276

-352,912

240,007

478,991

-3,441

468,084

27,792

118,997

-172,356

-370,670

59,414

-183,576

327,907

417,589

-59,325

141,566

-127,188

-53,137

60,663

139,268

0

0

0

Supplemental cash flow disclosures from investing and financing activities:
Assets acquired under financing lease obligation

-

-

-

-

-

-

-

-

-

3,271

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property, plant and equipment included in accounts payable and accrued expenses

-2,891

5,286

11,290

8,503

13,934

7,449

3,596

9,187

-588

2,566

5,624

6,648

11,248

6,363

3,093

2,474

2,050

2,089

564

567

565

387

1,875

1,987

2,711

1,924

0

0

0

Right-of-use assets obtained in exchange for operating lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Tenant improvements included in receivables and other current assets

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental cash flow disclosures:
Tenant improvements under financing lease included in tenant improvements receivable

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0